Mandate

Vinge has advised AMF Pensionsförsäkring in connection with the entry into of an agreement concerning the acquisition of 89.9% of Bergvik Skog Öst from BillerudKorsnäs Skog & Industri

June 24, 2019 M&A

Vinge has advised AMF Pensionsförsäkring AB in connection with an acquisition of 89.9% of the shares in BSÖ Holding AB, the owner of Bergvik Skog Öst AB, from BillerudKorsnäs Skog and Industri Aktiebolag.

The company was valued at SEK 12.2 billion on a debt‑free and cash‑free basis and covers a total of 363 000 hectares of land of which 295 000 hectares are productive forestry land primarily situated in central Sweden. As a part of the transaction, a long‑term agreement was entered into with BillerudKorsnäs for delivery of timber. The investment is AMF’s first direct investment in forestry.

The transaction is conditional upon approval by the Swedish Competition Authority.

Vinge’s team primarily consisted of Jonas Johansson, Carl Sander and Vilhelm Rondahl (M&A), Assur Badur and Karolina Cohrs (Real Property), Thomas Sjöberg and Johan Cederblad (Environmental) and Mathilda Persson (Commercial Agreements and IT).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024